New Pharmac drugs will 'significantly' impact quality of life for cancer patients - PM
New drugs for lung cancer and breast cancer, as well as a new treatment for multiple sclerosis will be funded by Pharmac, the Government announced today. In addition, access to a treatment for respiratory disease - pirfenidone, known by brand name Esbriet - will be widened. The drugs for non-small cell lung cancer and HER-2 positive metastatic breast cancer will be available from December 1. Health Minister David Clark said the drug funding would help 420 people, "including people living with advanced cancer". "Pharmac is currently consulting on three more cancer drugs - olaparib (Lynparza) for ovarian cancer, fulvestrant (Faslodex) for breast cancer and venetoclax (Venclexta) for chronic lymphocytic leukaemia," he said in a statement. The drugs funded from December 1 will be alectinib, known as Alecensa, for ALK positive advanced non-small cell lung cancer and trastuzumab emtansine, which goes by brand name Kadcyla, for HER-2 positive metastatic breast cancer.
"It will take time to modernise our approach to cancer care and control and improve survival rates, but today signifies good progress on the delivery of our plan," Mr Clark said.
==========================================================
What's the best way to keep grocery shopping bills down?
We are still feeling the pinch and the weekly shop is no different. So we are after your cost-saving tips please, neighbours!
What’s the best way you've found to cut down on your grocery bill? Share below (and hear tips from others!)
New Maths Curriculum
“children will be learning maths based on a new world-leading, knowledge-rich maths curriculum based on the best from across the OECD like Singapore and Australia, adapted for New Zealand”.
1 Kiwi + 1 Kiwi = 2 Kiwis
2 Sheep + 2 Sheep = 4 Sheep
1 Kiwi + 1 Stoat = 1 fat Stoat
… and THAT is why Maths is hard 😳
How much are you paying for your bin tags?
With bin tags on the way out, we want to hear how much you are still spending on them.
Loading…
